{"id":14237,"date":"2011-11-02T10:00:00","date_gmt":"2011-11-02T09:00:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/pfizer-triplica-utile-netto-iii-trimestre-alza-stime-2011\/"},"modified":"2011-11-02T10:00:00","modified_gmt":"2011-11-02T09:00:00","slug":"pfizer-triplica-utile-netto-iii-trimestre-alza-stime-2011","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/pfizer-triplica-utile-netto-iii-trimestre-alza-stime-2011\/","title":{"rendered":"Pfizer: third quarter net profit triples, raises 2011 estimates"},"content":{"rendered":"<p style=\"margin: 0cm 0cm 10pt\" class=\"MsoNormal\"><span style=\"line-height: 115%; font-family: &quot;Georgia&quot;,&quot;serif&quot;; color: #414144; font-size: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial; mso-fareast-language: IT\">New York, 01 November - Pfizer, the world leader in the pharmaceutical industry, tripled its net profit to 3.7 billion dollars in the third quarter compared to a year earlier and raised its 2011 estimates. So did the American group, whose results exceeded market expectations. Earnings per share for the quarter were 62 cents (from the 55-56 average expected by analysts) thanks in particular to the sale of the Capsugel division. Turnover increased by 7.48% to 17.2 billion, against expectations of 16.4 billion. For 2011, Pfizer raised its earnings per share estimates to $1.20-1.30, from $1.09-1.24 previously, and earnings adjusted for non-continuing operations to $2.24-2.29, from $2.16-2.26. Revenue forecasts were instead maintained at 66.2-67.2 billion. red-pal 01-11-11 12:44:20 (0129) 5<\/p>\n<p><\/span><\/p>\n<p style=\"margin: 0cm 0cm 10pt\" class=\"MsoNormal\"><span style=\"line-height: 115%; font-family: &quot;Georgia&quot;,&quot;serif&quot;; color: #414144; font-size: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial; mso-fareast-language: IT\">Corriere della sera.it<\/p>\n<p><\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>New York, 01 nov &#8211; Pfizer, leader mondiale nella farmaceutica, ha triplicato l&#8217;utile netto a 3,7 miliardi di dollari nel terzo trimestre verso un anno prima e ha alzato le stime 2011. Cosi&#8217; il gruppo americano, i cui risultati hanno superato le attese del mercato. L&#8217;utile per azione nel trimestre era pari a 62 centesimi &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-14237","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14237","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=14237"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14237\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=14237"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=14237"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=14237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}